-
Mashup Score: 1
What’s new? Most countries have set up population-based mammography screening programmes based on women’s age. However, the potential psychosocial harms, over-diagnosis, and increased costs together …
Source: Wiley Online LibraryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Assessing New Technologies in Surgery: Case Example of Acute Primary Repair of the Thumb Ulnar Collateral Ligament - 3 year(s) ago
Health technology assessment provides a means to assess the technical properties, safety, efficacy, cost-effectiveness, and ethical/legal/social impact of a novel technology. An important component of health technology assessment is the cost-effectiveness analysis (CEA), which can be performed using model-based CEA. This study used the CEA model to compare the cost-effectiveness of a novel…
Source: Journal of Hand SurgeryCategories: Latest Headlines, RheumatologyTweet-
Assessing New Technologies in #Surgery: Case Example of Acute Primary #Repair of the #Thumb #UlnarCollateralLigament @UofTMDprogram @UofTSurgery @Sunnybrook @UHN #CostEffectiveness #HealthTechnology #UCL #HandSurgery #OrthoTwitter #VisualAbstract https://t.co/nA2pq62sG7 https://t.co/MHIiEKGFbn
-
-
Mashup Score: 5Properly defining communities is paramount in protecting them - 3 year(s) ago
While much progress has been made since COVID immunizations first became available, there are still too many communities around the country where protection doesn’t run as deep as we need it to be.
Source: Modern HealthcareCategories: Healthcare Professionals, Latest HeadlinesTweet-
RE #costeffectiveness of #COVID19 #vaccinations we must define patient population to balance #healthequity w eff'cy https://t.co/d0zjZyFD2P @modrnhealthcr @DrOBarbot weighs #pophealth in #pandemic @miqedup reminds me of ur @LSEHealthPolicy class content for which I'm grateful
-
-
Mashup Score: 10
Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, the revised report finds the price range needed to reach standard cost-effectiveness thresholds is $3,000-$8,400, representing an 85%-95% discount from the announced list price.
Source: ICERCategories: Healthcare Professionals, Latest HeadlinesTweet-
More news on #Aduhelm #costeffectiveness via @icer_review Based on QALYs range = $3,000 - $8,400 vs $56,000 list price #ICER report details on different thresholds & social goals https://t.co/uLRLUqdeSW Public mtg 7-15 w @Biogen et al #Alzheimers #pharma #healthcosts #Aging https://t.co/pf8GPR1Wx5
-
-
Mashup Score: 1
“A national cost-effectiveness body or panel is definitely among the potential policy solutions,” said Rebecca Tisdale.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
Cost-effectiveness studies for widely used Medicare Part D drugs are few and far between.. https://t.co/aAaA97pS3a #pharma #Medicare #costeffectiveness
-
-
Mashup Score: 0
Rheumatoid arthritis (RA) has become an expensive disease to treat with the introduction of biological therapies in the early 2000s. Therefore, it is of crucial importance that researchers, together with clinicians, search for treatment strategies with the best value for money. That is why we would like to thank the authors of the paper entitled, “Effect on Costs and Quality-adjusted Life-years…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Editorial If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling Study @WietskesDREAM 📰 https://t.co/Hsj11pzUN9 #rheumatoidarthritis #costeffectiveness #clinicaltrials https://t.co/Y6EmlfLJPd
-
-
Mashup Score: 0
Chronic hepatitis C virus (HCV) infection, one of the most important public health problems in modern medicine, is responsible for approximately 71 million infections worldwide. The global disease burden of children with HCV infection aged 0-18 years is estimated to be 0.13%, corresponding with 3.26 million children.1 In 2018, the prevalence of children with HCV infection in the US and Europe was…
Source: The Journal of PediatricsCategories: Latest Headlines, PediatricsTweet-
In this #JPedsEditorial, Dr. Norberto Rodriguez-Baez discusses a study by Greenaway et al that addresses the #CostEffectiveness of early treatment of young #children with chronic #HepatitisC virus infection with new direct-acting #AntiviralTherapy. #HepC https://t.co/mHYP8RVDGm https://t.co/N6xePQA9os
-
-
Mashup Score: 0Cost‐Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First‐Line Therapy in Advanced Renal Cell Carcinoma in the U.S. - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Cost‐Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First‐Line Therapy in Advanced Renal Cell Carcinoma in the U.S. #CostEffectiveness #Pembrolizumab #Axitinib #Sunitinib #RenalCellCarcinoma #RCC https://t.co/4SMPKgEKiY https://t.co/uwFxOKEkYc
-
-
Mashup Score: 0Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective - 3 year(s) ago
Background: Durvalumab was approved by the FDA in February 2018 for patients with unresectable stage III NSCLC that has not progressed after platinum-based concurrent chemoradiotherapy (cCRT), and this regimen is the current standard of care. The objective of this study was to examine the cost-effectiveness of durvalumab following cCRT versus cCRT…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
JUST PUBLISHED: #CostEffectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III #NSCLC: A US Healthcare Perspective, by @RaneeMehra and colleagues: https://t.co/LssxaC5oVi #LCSM #hsronc #hpeonc https://t.co/rKZnUWIIdU
-
-
Mashup Score: 0Development and Internal Validation of a Risk Score to Detect Asymptomatic Carotid Stenosis - 3 year(s) ago
Asymptomatic carotid stenosis (ACS) is associated with an increased risk of ischaemic stroke and myocardial infarction. Risk scores have been developed to detect individuals at high risk of ACS, thereby enabling targeted screening, but previous external validation showed scope for refinement of prediction by adding additional predictors. The aim of this study was to develop a novel risk score in…
Categories: Cardiologists, Latest HeadlinesTweet-
Can a risk score for detecting significant carotid stenosis allow us to be more selective when ordering preop carotid ultrasound prior to cardiac surgery? #CostEffectiveness #CarotidStenosis #CTSurgery https://t.co/dVJOnmks1P https://t.co/EELec2bduR
-
#BCAM2021 Virtual Issue | Shah Alam Khan @DrSolangiAlam, et al. This @DKFZ #SystematicReview compares the #CostEffectiveness of risk-based #breastcancer screening with no screening, & age-based #screening in the general population 🔓Open access➡️https://t.co/JlEcyxEIum https://t.co/MUk21WZba6